New antibody drug tested for Hard-to-Treat cancers
NCT ID NCT06126666
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 22 times
Summary
This early-stage study tests a new drug called ABL103 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 96 participants will receive the drug intravenously, and researchers will monitor side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, Seoul, 13620, South Korea
Contact
Contact Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, Seoul, 03080, South Korea
Contact Email: •••••@•••••
-
Sevrance Hospital
RECRUITINGSeoul, South Korea, 03722, South Korea
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.